tbuckley/cabot-search huggingface dataset:
1024. Dual Targeted Vector for Multiple Myeloma Tumors and its Associated Angiogenesis
Authors: Louay K. Hallak, Jaime R. Merchan, Suzanne M. Greiner, Chris M. Storgard, Stephen J. Russell
Journal: Molecular Therapy (2004)

Top of pageAbstract
We have engineered an attenuated measles virus derived from the vaccine Edmonton strain to display the venom peptide echistatin with M28L mutation for targeting multiple myeloma tumors and associated angiogenesis. Echistatin binds irreversibly to integrin αVβ3 that has been shown by others to be expressed on activated endothelial cells and also on multiple myeloma tumor cells. We have chemically synthesized the echistatin gene and cloned it into p(+)MVGFP, a plasmid used to rescue measles virus, at the C-terminus of the gene coding for the viral attachment protein, H. Incorporation of the echistatin gene was confirmed by RT-PCR and the successful display of the protein as a C-terminal extension of H was demonstrated in replicating viruses by immunoblotting. Specific targeting of the virus was confirmed by infection of B10 cells (transformed Chinese Hamster Ovary cells) expressing the cognate receptor αVβ3. The recombinant measles virus displaying echistatin produced characteristic green syncytial rings, thereby, the vector was named emerald ring virus (ERV). Soluble echistatin peptide competitively inhibited ERV infection of B10 cells in a dose dependent manner. The growth kinetics of ERV showed similar characteristics to the wild type virus MV-Edm, but the titer was consistently about one log lower. In vitro, ERV infected primary cow pulmonary endothelial (CPAE) cells plated on matrigel more efficiently than the control virus, MV-Edm. Both MV-Edm and ERV infected human umbilical vein endothelial cells (HUVEC) in monolayer cultures, but when HUVEC formed capillary-like structures on matrigel, ERV infected the tubules more efficiently than MV-Edm. Although echistatin constitutes a toxin in snake venom, no toxicity was observed in ERV treated mice. ERV was injected intravenously or subcutaneously into SCID mice without any apparent toxicity. Chick chorioallantoic membrane (CAM) assay showed that ERV can infect bFGF-stimulated blood vessels. In an in vivo pilot study, ERV showed significant oncolytic activity against MM1 myeloma xenografts which are completely resistant to therapy with unmodified MV-Edm. In conclusion, we have explored the possibility of using a ligand derived from snake venom to display on measles virus. The ligand, echistatin, targets both activated endothelial cells and multiple myeloma cells.
Sentinel node biopsy in the management of primary cutaneous melanoma
Authors: R. Cerio, C. Harwood, S. Nicholson, L. McAndrew, P. Wells, G.C. Moir
Journal: British Journal of Dermatology (2005)

Conflicts of interest: none declared. Sir, We read with interest the arguments put forward regarding sentinel node evaluation.1, 2 Our skin tumour centre has been offering this procedure for nearly 3 years and has performed over 100 sentinel node biopsies (SNBs). Our data appear to concur with recently published data from St George's Hospital that microanatomical location of metastatic melanoma can go some way towards predicting nonsentinel lymph node involvement.3 Of course, only time will tell whether the procedure affects survival. There is no reason to expect a survival benefit from what is, in fact, a staging procedure. Surely, regardless of the argument put forward by the opposing experts, the overwhelming reason to perform SNB is for accurate staging of disease, thereby offering the patient the opportunity to participate in national trials. Without accurate staging any melanoma trial for stage III disease will be useless. Unfortunately, to date, unlike SNB, advances in imaging techniques and serology such as measurement of lactate dehydrogenase and S100 protein levels have failed to enable accurate staging of many patients with microscopic disease.
Cognitive Phenotypes and Genomic Copy Number Variations
Authors: James R. Lupski
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oro‐hepatic link, endotoxemia, and systemic inflammation: The role of chronic periodontitis
Authors: Fredrik Åberg, Jaana Helenius‐Hietala
Journal: Hepatology (2015)

Potential conflict of interest: Nothing to report. To the Editor: We read with great interest the recent study by Bajaj et al.1 and the accompanying editorial, suggesting that salivary dysbiosis in liver cirrhosis is linked to an oral proinflammatory environment, systemic inflammation, and a risk for subsequent liver‐related hospitalization. Systemic endotoxemia, typically originating from the gut, is associated with liver damage, progression of liver disease, and cirrhosis decompensation. Bajaj et al.1 suggest an additional role of oral microbiota toward the overall endotoxemia and systemic inflammation in cirrhosis. In their study, 9% of patients (15 of 167) in the initial cohort screened were excluded owing to present periodontitis/gingival disease or ongoing dental treatment.1 However, detailed criteria for periodontitis/gingival disease are not stated. As concluded by the researchers, patients with periodontitis may have greater salivary dysbiosis. We have shown that, after careful oral examination, on average, one to two teeth needed extraction because of severe periodontitis in patients with alcoholic liver cirrhosis under evaluation for liver transplantation (LT)2; this demonstrates high prevalence of periodontitis in advanced liver cirrhosis. In periodontitis, inflamed gingival tissues can release periodontal bacteria, their toxins, and locally produced cytokines into the bloodstream, resulting in systemic inflammation.3 Extensively inflamed periodontal tissues are comparable to an open wound the size of a human palm. Periodontitis‐associated endotoxemia has been shown to induce liver injury in rats.4 Moreover, among patients with cirrhosis under evaluation for LT, we recently reported a correlation between dental infections and accelerated progression of liver disease.5 This was evident as a shorter time from liver disease diagnosis to need for transplantation and a faster progression of the Model for End‐Stage Liver Disease score over a 1‐year follow‐up.5 These findings extend the emerging evidence of an oro‐hepatic link, and periodontitis might be a more powerful driver of endotoxemia, systemic inflammation, and liver damage than salivary dysbiosis alone. If these suggested adverse effects of periodontitis on liver disease are confirmed in appropriate prospective studies, dental care may assume a role in the management of patients with liver disease. The study by Bajaj et al. show exciting promise in that salivary‐microbiota testing may become a prognostic marker in liver cirrhosis; however, in interpreting such tests, close attention to oral health status is important.
Exposure to cadmium‐contaminated soils increases allergenicity of <i>Poa annua</i> L. pollen
Authors: R. Aina, R. Asero, A. Ghiani, G. Marconi, E. Albertini, S. Citterio
Journal: Allergy (2010)

Pollution is considered as one main cause for the increase of allergic diseases. Air pollutants may cause and worsen airway diseases and are probably able to make pollen allergens more aggressive. Previous studies looked at traffic-related air pollution, but no data about the effects of polluted soils on pollen allergens are available. We aimed to assess the effects of plant exposure to cadmium-contaminated soil on allergenicity of the annual blue grass, Poa annua L, pollen.Poa plants were grown in soil contaminated or not contaminated (control) with cadmium. At flowering, mature pollen was analyzed by microscopy, to calculate the percentage of pollen grains releasing cytoplasmic granules, and by proteomic techniques to analyze allergen proteins. Allergens were identified by sera from grass pollen-allergic patients and by mass spectrometry.Pollen from Cd-exposed plants released a higher amount of allergenic proteins than control plants. Moreover, Cd-exposed pollen released allergens-containing cytoplasmic grains much more promptly than control pollen. Group 1 and 5 allergens, the major grass pollen allergens, were detected both in control and Cd-exposed extracts. These were the only allergens reacting with patient's sera in control pollen, whereas additional proteins strengthening the signal in the gel region reacting with patient's sera were present in Cd-exposed pollen. These included a pectinesterase, a lipase, a nuclease, and a secretory peroxydase. Moreover, a PR3 class I chitinase-like protein was also immunodetected in exposed plants.Pollen content of plants grown in Cd-contaminated soils is more easily released in the environment and also shows an increased propensity to bind specific IgE.
DRUG REACTIONS X.
Authors: John Almeyda, Harvey Baker
Journal: British Journal of Dermatology (1970)

Journal Article DRUG REACTIONS X: Adverse Cutaneous Reactions to Hypoglycaemic Agents Get access John Almeyda, John Almeyda The London Hospital London, E.1 Search for other works by this author on: Oxford Academic Google Scholar Harvey Baker Harvey Baker The London Hospital London, E.1 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 82, Issue 6, 1 June 1970, Pages 634–637, https://doi.org/10.1111/j.1365-2133.1970.tb06111.x Published: 01 June 1970
Abstract 1754: Cycloartane anticancer activity
Authors: Henry Isaac Cloore Lowe, Ngeh J. Toyang, Charah Watson, Joseph Bryant
Journal: Cancer Research (2014)

Abstract New cancer diagnoses remain on the rise despite significant improvements in early detection and treatment. The role of Kinases in cancer onset and progression has made kinases a target for the control of some cancers. The MRCKα/β kinases have recently been implicated in cancer onset and progression and as such could serve as a potential drug target. The discovery that kinases are most effectively inhibited by small molecules has also resulted in an increased search for small molecule kinase inhibitors. Cycloartanes are small molecules found in many medicinal plants including the Jamaican Ball Moss (Tillandsia recurvata). Recent studies on T. recurvata have demonstrated that it possesses significant anticancer activity. Cycloartane-3,24,25-triol, an analog of a cycloartane identified in Ball moss was also shown to have inhibitory activity against MRCKα kinase. This study was as such set up to determine the MRCKα/β kinase inhibition activity of other cycloartanes in Ball Moss and their analogs. The kinase inhibitory activity of 6 cycloartanes was investigated using the ligand-kinase binding assay while the WST-1 reagent assay was used to determine the antiproliferative activity of the cycloartanes against some prostate and breast cancer cell lines. Cycloart-23-ene-3,25-diol (1), Cycloartane-3,24,25-triol (2), Cycloart-25-ene-3,24-diol (3), 3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acid (4), 24,25-Dihydroxycycloartan-3-one (5) inhibited the MRCKα kinase with Kd of 0.21 μM, 0.25µM, 0.36 µM, 3.0 µM, and 2.1 µM respectively. Hydroxycycloart-23-en-3-one,25, (6) showed no inhibition against the MRCKα kinase. Compounds 1, 3, 4, 5 inhibited the MRCKβ kinase with Kd of 4.7 μM, 1.10 µM, 3.2 µM, and 9.8 µM, respectively. Three of the six cycloartanes exhibited antiproliferation activity against two prostate and breast cancer cell lines each. In conclusion, cycloart-23-ene-3,25-diol (1) showed the most promising activity against the MRCKα/β kinase out of the 6 cycloartanes screened demonstrating an interesting structure activity relationship profile when compared with the other molecules. Cycloart-23-ene-3,25-diol (1) deserves further studies to determine its in vivo efficacy and safety. Citation Format: Henry Isaac Cloore Lowe, Ngeh J. Toyang, Charah Watson, Joseph Bryant. Cycloartane anticancer activity. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1754. doi:10.1158/1538-7445.AM2014-1754
Prioritizing Influenza Vaccination
Authors: Michael Rothberg
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2513: Optimization Of CRT Timing By Fusion In ECG Lead V1 Is Associated With A Higher Increase In Left-Ventricular Contractility
Authors: Russell Bailey, Richard Shepard, Kevin Hsu, Matt Zmijewski, John Roberts, Aleksandre Sambelashvili
Journal: Circulation (2007)

Introduction: Optimization of CRT timing can result in improvement in cardiac function and long-term clinical outcome in CRT patients. Previous studies in LBBB canines have shown that the maximal i...
Naevoid hyperkeratosis of the nipple and areola in a man
Authors: Y. Kubota, T. Koga, J. Nakayama, H. Kiryu
Journal: British Journal of Dermatology (2000)

S ir, Hyperkeratosis of the nipple and areola (HNA) is a rare benign condition characterized by verrucous thickening and brownish discoloration of the nipples and areolae. Three types have been proposed: 1 (i) extension of epidermal naevus; (ii) related to ichthyosis; and (iii) a naevoid form. The third type, called naevoid hyperkeratosis, is usually bilateral, asymptomatic and appears either at puberty or during pregnancy in females. 1 Very few men have been reported to have naevoid hyperkeratosis, and most had a medical history of prostatic adenocarcinoma treated by oestrogen therapy. 2, 3 We report a very unusual case of unilateral naevoid hyperkeratosis of the areola occurring in a Japanese man who had never received oestrogen therapy. A 33‐year‐old Japanese man presented with thickened warty skin of his right areola and pigmentation around both areolae which had been present for 20 years. He had scratched his chest bilaterally because of itch which had developed after he had been stung on the right breast by an insect at the age of 10 years. New warty lesions gradually appeared around his right areola while scratching. There was no personal or family history of viral warts, epidermal naevi or ichthyosis. Examination revealed the patient's right areola to be hyperpigmented and verrucous, sparing the central portion of the nipple itself ( Fig. 1a). The left areola showed only hyperpigmentation, without a thickened or verrucous appearance. He had no xerosis of the skin. Examination of intertriginous areas did not reveal any evidence of acanthosis nigricans. He had no underlying malignancy or endocrinopathy. In addition, he had no history of using any oestrogen‐containing medication. Histopathological examination of the right areola showed extensive and marked elongations of rete ridges of the epidermis and papillary dermis, inducing filiform acanthosis and papillomatosis. An orthokeratotic hyperkeratosis with occasional keratotic plugging was observed. In addition, some anastomosing strands of elongated ridges and variably sized horn cysts were seen. The basal layer of the epidermis was hyperpigmented, but there was no melanocytic proliferation. The elongated papillary dermis was oedematous, but the collagen fibres were somewhat thickened and sclerotic, and a mild perivascular lymphocytic inflammatory infiltrate was found in the dermis (Fig. 1b). We diagnosed this patient as having naevoid hyperkeratosis, based upon the clinical warty lesion and the histopathological findings. Cryotherapy with liquid nitrogen was used as the initial treatment; the lesion immediately diminished and further light cryotherapy of 15 s each treatment was given at 2‐week intervals. Part of the hyperpigmented and hyperkeratotic lesion clearly disappeared after six treatments. No relapse has been observed during 3 months' follow‐up.
Abstract 14023: Inhibition of the Age-induced microRNA-34 Improves Recovery After AMI in Mice
Authors: Reinier A Boon, Kazuma Iekushi, Ariane Fischer, Susanne Heydt, Guillaume Carmona, Anton Horrevoets, Angelika Bonauer, Andreas M Zeiher, Stefanie Dimmeler
Journal: Circulation (2010)
Fortnightly Review: Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk?
Authors: D G Beevers, P Sleight
Journal: BMJ (1996)

<h3>Summary points</h3> Only thiazide diuretics and β blockers have been shown to prevent myocardial infarction and stroke in properly randomised and blinded studies in patients with hypertension The efficacy of calcium channel blockers and angiotensin converting enzyme inhibitors in preventing myocardial infarction and stroke and reducing mortality in hypertensive patients has not been studied The current licensing and clinical use of calcium channel blockers and angiotensin converting enzyme inhibitors in hypertension have been based on surrogate end points such as reduction of blood pressure or left ventricular hypertrophy, or both, or reduction of microproteinuria or macroproteinuria Observational data on short acting dihydropyrridine calcium channel blockers are worrying; there is urgent need for proper large scale randomised trials of calcium channel blockers in hypertension Trials in ischaemic heart disease suggest that in the absence of left ventricular dysfunction verapamil and diltiazem are preferred choices if a calcium, channel blocker is needed in the non-acute setting
Six-minute walk test: Comparison with cardiopulmonary exercise test performance, lung function and arterial blood gases in patients with bronchiectasis
Authors: Isabel Gomes, Mafalda van Zeller, Patrícia Caetano Mota, Paulo Viana, Cristina Carrondo, Ana Dantas, João Almeida, Agostinho Marques
Journal: European Respiratory Journal (2011)

Background:  Relationships between the 6-minute walk test (6MWT) and cardiopulmonary exercise test (CPET) performance have been established in some respiratory diseases. However, in patients with bronchiectasis (BECTs) data are scant in the literature.   Aim:  To evaluate relationships between 6MWT distance and CPET performance, lung function (LF) and arterial blood gases (ABG) in patients with stable bronchiectasis.   Methods:  A retrospective evaluation of 27 patients with BECTs who attended a rehabilitation program and who had 6MWT, CPET in cycle ergometer, LF and ABG (at rest) evaluation at the start of the program. Spearman9s correlation coefficient was used for statistical analysis.   Results:  Thirteen male and 14 female with ages ranging from 19 to 75 (median 51 yrs). Sixteen patients were severely obstructed and 11 had airway colonisation. Mean 6MWT distance was 440,4 meters and mean end test saturation was 89,30%. Mean maximal work (MW) was 68,1 Watts and mean end-CPET saturation was 89,37%. Positive correlations were found between 6MWT distance and MW (r=0.721**; p=0.000), VO2max (r=0.551**; p=0.003), VO2max/kg (r=0.497**; p=0.008), PaO2 (r=0.485*; p=0.010) and HgbSat (r=0.481*; p=0.013). No correlations were found between 6MWT distance and FVC, FEV1, FEV1/FVC, residual volume or PaCO2. Considering colonised patients, positive correlations were found between 6MWT distance and VO2max, VO2max/kg, PaO2 and HgbSat at the 0.05 level.   Conclusions:  6MWT is a simple test that seems to mirror exercise capacity evaluated by CPET in patients with bronchiectasis. None of the LF parameters evaluated reflected 6MWT distance in these patients.
RVX-208
Authors: Dana Bailey, Ravi Jahagirdar, Allan Gordon, Anouar Hafiane, Steven Campbell, Safia Chatur, Gregory S. Wagner, Henrik C. Hansen, Fabrizio S. Chiacchia, Jan Johansson, Larbi Krimbou, Norman C.W. Wong, Jacques Genest
Journal: Journal of the American College of Cardiology (2010)